Isabelle Ragueneau‐Majlessi

Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug

Md L T Vieira, Brian J. Kirby, Isabelle Ragueneau‐Majlessi et al. · Clinical Pharmacology & Therapeutics · 2013 · 101 citations

Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016

Jingjing Yu, Zhu Zhou, Jessica Tay-Sontheimer et al. · Drug Metabolism and Disposition · 2018 · 90 citations · Full text

Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation Study

Ping Zhao, Isabelle Ragueneau‐Majlessi, Lei Zhang et al. · The Journal of Clinical Pharmacology · 2009 · 84 citations · Full text

Medicinal Chemistry, Pharmaceutical Science, Cyp3a Substrates +15

Levetiracetam Does Not Alter the Pharmacokinetics of an Oral Contraceptive in Healthy Women

Isabelle Ragueneau‐Majlessi, René H. Levy, Franz Janik · Epilepsia · 2002 · 75 citations · Full text

Hormonal Contraceptive, Oral Contraceptive, Gynecology +17

A useful tool for drug interaction evaluation: The University of Washington Metabolism and Transport Drug Interaction Database

Houda Hachad, Isabelle Ragueneau‐Majlessi, René H. Levy · Human Genomics · 2010 · 71 citations · Full text